Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 monoclonal antibody conjugated to a derivative of an antitumor antibiotic, calicheamicin. GO was approved for the treatment of relapsed acute myeloid leukemia (AML) ...Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 monoclonal antibody conjugated to a derivative of an antitumor antibiotic, calicheamicin. GO was approved for the treatment of relapsed acute myeloid leukemia (AML) in the United States (US) in 2000. However, GO was withdrawn from the US market in June 2010, because a large-scale clinical trial failed to show additive or synergistic effects with conventional chemotherapy for newly diagnosed AML. GO is currently available only in Japan. However, several large clinical studies have demonstrated beneficial effects of GO when added to chemotherapy for AML in recent years;therefore, reconsideration of GO availability is gaining attention. Therefore, the role and efficacy of GO as monotherapy or in combination therapy for de novo or relapsed AML should be positively investigated.展开更多
We performed a retrospective analysis of 9 patients with acute myeloid leukemia (AML) treated with gemtuzumab ozogamicin (GO) plus cytarabine as a salvage regimen (GO reinduction) for patients who did not achieve comp...We performed a retrospective analysis of 9 patients with acute myeloid leukemia (AML) treated with gemtuzumab ozogamicin (GO) plus cytarabine as a salvage regimen (GO reinduction) for patients who did not achieve complete remission (CR) after the first cycle of induction chemotherapy or at first relapse. Cases of AML secondary to myelodysplastic syndrome or myeloproliferative disorder were included. CR was achieved in 6 of 9 patients, and 2 of 6 responders became long-term survivors. No non-responders survived longer than 6 months. Toxicity was mild, and the median duration of myelosuppression was less than 30 days. Stomatitis, nausea and sepsis occurred as non-hematological adverse events. Although our sample size was too small to permit definitive conclusions, GO reinduction should be considered for patients who relapse or do not achieve CR after the first cycle of induction chemotherapy. Some AML subtypes may respond more robustly than others, and further investigation is warranted.展开更多
1文献来源Amadori S,Suciu S,Selleslag D,et al.Gemtuzumab Ozogamicin versus best supportive carein older patients with newly diagnosed acute myeloidleukemia unsuitable for intensive chemotherapy：Results of the randomiz...1文献来源Amadori S,Suciu S,Selleslag D,et al.Gemtuzumab Ozogamicin versus best supportive carein older patients with newly diagnosed acute myeloidleukemia unsuitable for intensive chemotherapy：Results of the randomized phaseⅢEORTC-GIMEMAAML-19 trial[J].J Clin Oncol,2016,34（9）：972-979.2证据水平1b。展开更多
Acute myeloid leukemia(AML)is a heterogeneous clonal disorder of myeloid precursors arrested in their matura-tion,creating a diverse disease entity with a wide range of responses to historically standard treatment app...Acute myeloid leukemia(AML)is a heterogeneous clonal disorder of myeloid precursors arrested in their matura-tion,creating a diverse disease entity with a wide range of responses to historically standard treatment approaches.While signifi cant progress has been made in character-izing and individualizing the disease at diagnosis to op-timally inform those affected,progress in treatment to reduce relapse and induce remission has been limited thus far.In addition to a brief summary of the factors that shape prognostication at diagnosis,this review attempts to expand on the current therapies under investigation that have shown promise in treating AML,including hy-pomethylating agents,gemtuzumab ozogamicin,FLT3 ty-rosine kinase inhibitors,antisense oligonucleotides,and other novel therapies,including aurora kinases,mTOR and PI3 kinase inhibitors,PIM kinase inhibitors,HDAC inhibitors,and IDH targeted therapies.With these,and undoubtedly many others in the future,it is the hope that by combining more accurate prognostication with more effective therapies,patients will begin to have a different,and more complete,outlook on their disease that allows for safer and more successful treatment strategies.展开更多
文摘Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 monoclonal antibody conjugated to a derivative of an antitumor antibiotic, calicheamicin. GO was approved for the treatment of relapsed acute myeloid leukemia (AML) in the United States (US) in 2000. However, GO was withdrawn from the US market in June 2010, because a large-scale clinical trial failed to show additive or synergistic effects with conventional chemotherapy for newly diagnosed AML. GO is currently available only in Japan. However, several large clinical studies have demonstrated beneficial effects of GO when added to chemotherapy for AML in recent years;therefore, reconsideration of GO availability is gaining attention. Therefore, the role and efficacy of GO as monotherapy or in combination therapy for de novo or relapsed AML should be positively investigated.
文摘We performed a retrospective analysis of 9 patients with acute myeloid leukemia (AML) treated with gemtuzumab ozogamicin (GO) plus cytarabine as a salvage regimen (GO reinduction) for patients who did not achieve complete remission (CR) after the first cycle of induction chemotherapy or at first relapse. Cases of AML secondary to myelodysplastic syndrome or myeloproliferative disorder were included. CR was achieved in 6 of 9 patients, and 2 of 6 responders became long-term survivors. No non-responders survived longer than 6 months. Toxicity was mild, and the median duration of myelosuppression was less than 30 days. Stomatitis, nausea and sepsis occurred as non-hematological adverse events. Although our sample size was too small to permit definitive conclusions, GO reinduction should be considered for patients who relapse or do not achieve CR after the first cycle of induction chemotherapy. Some AML subtypes may respond more robustly than others, and further investigation is warranted.
文摘1文献来源Amadori S,Suciu S,Selleslag D,et al.Gemtuzumab Ozogamicin versus best supportive carein older patients with newly diagnosed acute myeloidleukemia unsuitable for intensive chemotherapy：Results of the randomized phaseⅢEORTC-GIMEMAAML-19 trial[J].J Clin Oncol,2016,34（9）：972-979.2证据水平1b。
文摘Acute myeloid leukemia(AML)is a heterogeneous clonal disorder of myeloid precursors arrested in their matura-tion,creating a diverse disease entity with a wide range of responses to historically standard treatment approaches.While signifi cant progress has been made in character-izing and individualizing the disease at diagnosis to op-timally inform those affected,progress in treatment to reduce relapse and induce remission has been limited thus far.In addition to a brief summary of the factors that shape prognostication at diagnosis,this review attempts to expand on the current therapies under investigation that have shown promise in treating AML,including hy-pomethylating agents,gemtuzumab ozogamicin,FLT3 ty-rosine kinase inhibitors,antisense oligonucleotides,and other novel therapies,including aurora kinases,mTOR and PI3 kinase inhibitors,PIM kinase inhibitors,HDAC inhibitors,and IDH targeted therapies.With these,and undoubtedly many others in the future,it is the hope that by combining more accurate prognostication with more effective therapies,patients will begin to have a different,and more complete,outlook on their disease that allows for safer and more successful treatment strategies.
